Roivant Sciences (ROIV) said Tuesday its Kinevant Sciences unit's phase 2 Resolve-Lung trial for namilumab in chronic active pulmonary sarcoidosis failed to meet its primary and secondary endpoints.
Namilumab failed to meet the primary endpoint, showing no treatment benefit over placebo in reducing Rescue Events during the double-blind period. Secondary endpoints, including changes in lung function, corticosteroid tapering success, also did not demonstrate efficacy, it added.
Despite a safety profile consistent with earlier studies, Kinevant will discontinue namilumab's development for sarcoidosis.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。